AstraZeneca COVID-19 vaccine shows 74% efficacy in large U.S. trial
CHICAGO — AstraZeneca Plc’s COVID-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease, a figure that increased to 83.5% in people aged 65…
Stay updated with breaking news from Executive Pascal Soriot. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CHICAGO — AstraZeneca Plc’s COVID-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease, a figure that increased to 83.5% in people aged 65…
Efficacy increased to 83.5% in people aged 65 and older, according to the company's US clinical trial.. Read more at straitstimes.com.
CHICAGO, Sept 30 — AstraZeneca Plc’s Covid-19 vaccine demonstrated 74 per cent efficacy at preventing symptomatic disease, a figure that increased to 83.5 per cent in people aged 65 and older, according to long-awaited results of the company’s US clinical trial published on Wednesday. Overall...
AstraZeneca Plc's Covid-19 vaccine demonstrated 74 percent efficacy at preventing symptomatic disease, a figure that increased to 83.5 percent in people aged 65 and older, according to long-awaited results of the company's US clinical trial published on Wednesday.
Overall efficacy of 74% was lower than the interim 79% figure reported by the British drugmaker in March, a result AstraZeneca revised days later to 76% after a rare public rebuke from health officials